Theravance Biopharma (TBPH) Research & Development (2013 - 2026)
Theravance Biopharma (TBPH) posted quarterly Research & Development of $5.8 million for Q1 2026, down 49.1% year-over-year from $11.5 million in Q1 2025, and down 20.8% quarter-over-quarter from $7.4 million in Q4 2025.
Theravance Biopharma (TBPH) Research & Development (2013 - 2026) Analysis & Trends
Theravance Biopharma (TBPH) has reported Research & Development for 14 consecutive years, with $5.8 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Research & Development fell 49.1% year-over-year to $5.8 million; the TTM figure through Mar 2026 stood at $31.8 million (down 20.77% YoY), while the FY2025 annual figure was $37.4 million, down 0.61% from the prior year.
- Research & Development fell to $5.8 million in Q1 2026 per TBPH's latest filing, from $7.4 million in the prior quarter.
- Across five years, Research & Development topped out at $23.3 million in Q1 2022 and bottomed at $5.8 million in Q1 2026.
- Historically, Research & Development has averaged $10.9 million across 5 years, with a median of $9.5 million in 2024.
- Annual changes were most pronounced in 2022 — Research & Development tumbled 77.44% — and 2025, when it gained 27.7%.
- Theravance Biopharma's Research & Development stood at $15.3 million in 2022, then sank by 45.84% to $8.3 million in 2023, then advanced by 13.71% to $9.5 million in 2024, then decreased by 22.14% to $7.4 million in 2025, then slipped by 20.8% to $5.8 million in 2026.
- Business Quant data shows TBPH's Research & Development at $5.8 million in Q1 2026, $7.4 million in Q4 2025, and $8.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.37 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 394.92 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 612.28 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 1,146.05 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 97.90 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 413.13 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 210.03 Mn |
| 10 | Theravance Biopharma | 880.59 Mn | 492.93 Mn | - | 4.71 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 4.71 Mn |
| Mar 31, 2026 | 5.83 Mn |
| Dec 31, 2025 | 7.36 Mn |
| Sep 30, 2025 | 8.11 Mn |
| Jun 30, 2025 | 10.49 Mn |
| Mar 31, 2025 | 11.45 Mn |
| Dec 31, 2024 | 9.45 Mn |
| Sep 30, 2024 | 9.27 Mn |
| Jun 30, 2024 | 9.95 Mn |
| Mar 31, 2024 | 8.97 Mn |
| Dec 31, 2023 | 8.31 Mn |
| Sep 30, 2023 | 8.31 Mn |
| Jun 30, 2023 | 9.43 Mn |
| Mar 31, 2023 | 14.57 Mn |
| Dec 31, 2022 | 15.35 Mn |
| Sep 30, 2022 | 9.87 Mn |
| Jun 30, 2022 | 14.92 Mn |
| Mar 31, 2022 | 23.25 Mn |
| Dec 31, 2021 | 31.23 Mn |
| Sep 30, 2021 | 43.74 Mn |